MWMark N. Warden

Mark N. Warden

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mark N. Warden has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Statistical approaches for the integration of external controls in a cystic fibrosis clinical trial: a simulation and an application

    by Mark N Warden, Sonya L Heltshe, Noah Simon, Stephen J Mooney, Nicole Mayer-Hamblett, Amalia S Magaret

    Development of new therapeutics for a rare disease such as cystic fibrosis is hindered by challenges in accruing enough patients for clinical trials. Use of external controls from well-matched historical trials can reduce prospective trial sizes, and this approach has supported regulatory approval of new interventions for other rare diseases. Here we consider 3 statistical methods that incorporate external controls into a hypothetical clinical trial of a new treatment to reduce pulmonary exacerbations in cystic fibrosis patients: (1) inverse probability weighting, (2) bayesian modeling with propensity-score–based power priors, and (3) hierarchical bayesian modeling with commensurate priors. We compare the methods via simulation study and in a real clinical-trial data setting. Simulations showed that bias in the treatment effect was less than 4% using any of the methods, with type I error (or in the bayesian cases, posterior probability of the null hypothesis) usually less than 5%. Inverse probability weighting was sensitive to similarity in prevalence of the covariates between historical and prospective trial populations. The commensurate prior method performed best with real clinical trial data. Using external controls to reduce trial size in future clinical trials holds promise and can advance the therapeutic pipeline for rare diseases. This article is part of a Special Collection on Pharmacoepidemiology.


  • Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis

    by E.T. Zemanick, I. Emerman, M. McCreary, N. Mayer-Hamblett, M.N. Warden, K. Odem-Davis, D.R. VanDevanter, C.L. Ren, J. Young, M.W. Konstan


  • Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study

    by N Mayer-Hamblett, E T Zemanick, K Odem-Davis, D VanDevanter, M Warden, S M Rowe, J Young, M W Konstan


  • Open Access

    A comparison of prediction approaches for identifying prodromal Parkinson disease

    by Mark N. Warden, Susan Searles Nielsen, Alejandra Camacho-Soto, Roman Garnett, Brad A. Racette

    Identifying people with Parkinson disease during the prodromal period, including via algorithms in administrative claims data, is an important research and clinical priority. We sought to improve upon an existing penalized logistic regression model, based on diagnosis and procedure codes, by adding prescription medication data or using machine learning. Using Medicare Part D beneficiaries age 66–90 from a population-based case-control study of incident Parkinson disease, we fit a penalized logistic regression both with and without Part D data. We also built a predictive algorithm using a random forest classifier for comparison. In a combined approach, we introduced the probability of Parkinson disease from the random forest, as a predictor in the penalized regression model. We calculated the receiver operator characteristic area under the curve (AUC) for each model. All models performed well, with AUCs ranging from 0.824 (simplest model) to 0.835 (combined approach). We conclude that medication data and random forests improve Parkinson disease prediction, but are not essential.


  • Open Access

    Solvent exposed occupations and risk of Parkinson disease in Finland

    by Susan Searles Nielsen, Mark N. Warden, Markku Sallmén, Markku Sainio, Sanni Uuksulainen, Harvey Checkoway, Christer Hublin, Brad A. Racette


  • [ 18 F]FDOPA positron emission tomography in manganese-exposed workers

    by Susan R. Criswell, Susan Searles Nielsen, Mark Warden, Joel S. Perlmutter, Stephen M. Moerlein, Hubert P. Flores, John Huang, Lianne Sheppard, Noah Seixas, Harvey Checkoway, et al.


  • A predictive model to identify Parkinson disease from administrative claims data

    by Susan Searles Nielsen, Mark N. Warden, Alejandra Camacho-Soto, Allison W. Willis, Brenton A. Wright, Brad A. Racette

    Objective: To use administrative medical claims data to identify patients with incident Parkinson disease (PD) prior to diagnosis. Methods: Using a population-based case-control study of incident PD in 2009 among Medicare beneficiaries aged 66–90 years (89,790 cases, 118,095 controls) and the elastic net algorithm, we developed a cross-validated model for predicting PD using only demographic data and 2004–2009 Medicare claims data. We then compared this model to more basic models containing only demographic data and diagnosis codes for constipation, taste/smell disturbance, and REM sleep behavior disorder, using each model9s receiver operator characteristic area under the curve (AUC). Results: We observed all established associations between PD and age, sex, race/ethnicity, tobacco smoking, and the above medical conditions. A model with those predictors had an AUC of only 0.670 (95% confidence interval [CI] 0.668–0.673). In contrast, the AUC for a predictive model with 536 diagnosis and procedure codes was 0.857 (95% CI 0.855–0.859). At the optimal cut point, sensitivity was 73.5% and specificity was 83.2%. Conclusions: Using only demographic data and selected diagnosis and procedure codes readily available in administrative claims data, it is possible to identify individuals with a high probability of eventually being diagnosed with PD.


  • Dose-dependent progression of parkinsonism in manganese-exposed welders

    by Brad A. Racette, Susan Searles Nielsen, Susan R. Criswell, Lianne Sheppard, Noah Seixas, Mark N. Warden, Harvey Checkoway

    Objective: To determine whether the parkinsonian phenotype prevalent in welders is progressive, and whether progression is related to degree of exposure to manganese (Mn)-containing welding fume. Methods: This was a trade union–based longitudinal cohort study of 886 American welding-exposed workers with 1,492 examinations by a movement disorders specialist, including 398 workers with 606 follow-up examinations up to 9.9 years after baseline. We performed linear mixed model regression with cumulative Mn exposure as the independent variable and annual change in Unified Parkinson Disease Rating Scale motor subsection part 3 (UPDRS3) as the primary outcome, and subcategories of the UPDRS3 as secondary outcomes. The primary exposure metric was cumulative Mn exposure in mg Mn/m3-year estimated from detailed work histories. Results: Progression of parkinsonism increased with cumulative Mn exposure. Specifically, we observed an annual change in UPDRS3 of 0.24 (95% confidence interval 0.10–0.38) for each mg Mn/m3-year of exposure. Exposure was most strongly associated with progression of upper limb bradykinesia, upper and lower limb rigidity, and impairment of speech and facial expression. The association between welding exposure and progression appeared particularly marked in welders who did flux core arc welding in a confined space or workers whose baseline examination was within 5 years of first welding exposure. Conclusions: Exposure to Mn-containing welding fume may cause a dose-dependent progression of parkinsonism, especially upper limb bradykinesia, limb rigidity, and impairment of speech and facial expression.